Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2011. The report details a specific share repurchase transaction executed on May 3, 2011, in accordance with shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 400,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,318.0 pence per share; lowest price paid was 1,312.5 pence per share.
- Treasury Shares Held: 493,224,284 shares (representing 8.72% of total issued share capital and 9.55% of total voting rights).
- Shares in Issue: 5,163,907,153 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the cancellation of the 400,000 shares purchased on May 3, 2011. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of Treasury shares held (493,224,284) against the latest annual report.
- Confirm the total issued share capital excluding Treasury shares (5,163,907,153) for voting rights calculations.
- Review the price paid per share (1,312.5 to 1,318.0 pence) against market prices on May 3, 2011.
- Note that the purchased shares were cancelled, reducing the total share count.